Apr 3 2012
Meda (STO:MEDAA) has established an affiliate in Hong Kong. At the end of 2011, Meda opened its China affiliate based in Beijing. Meda will begin by commercializing two of its well-established products in Hong Kong; Elidel for the treatment of atopic dermatitis (eczema) and azelastine for the treatment of allergic rhinitis (AR).
"We are committed to investing in new promising geographic markets and we anticipate that our product pipeline has the potential for significant growth in Asia", said Anders Lönner, CEO of Meda AB.